Please login to the form below
CNS
This page shows the latest CNS news and features for those working in and with pharma, biotech and healthcare.
Stop that!
Stop that! Back to the strategy workshop. The clients, on a verge of a huge investment in CNS, wanted to anticipate the market but, still in a reductionist prison, was focused
Latest news
-
AZ’s Tagrisso cuts risk of EGFR-positive NSCLC spreading to the brain
In addition, Tagrisso treatment also reduced the risk of CNS recurrence or death by 82%, although median CNS DFS was not reached yet in either arm of the study. ... According to AZ, CNS recurrence – in which the cancer spreads to the brain – is
-
Shionogi makes buyout play for Tetra ahead of Alzheimer’s readout
This new collaboration with Tetra reinforces our steadfast commitment to advancing cutting-edge science in central nervous system (CNS) disorders including Alzheimer’s disease,” he added.
-
Nektar’s opioid analgesic slammed with FDA panel rejection
According to Nektar, NKTR-181 provides the same levels of pain relief as standard opioid products, but with reduced central nervous system (CNS) side-effects, namely euphoria.
-
Intra-Cellular soars on FDA approval of schizophrenia drug
According to Matteis, the Caplyta approval indicates that regulators will “often look at a mixed efficacy package in CNS through a 'glass half full lens'," due to the increased need for
-
FDA clears SK Life Science’s anti-epileptic drug Xcopri
Today’s approval is a major step toward our goal of becoming a fully-integrated global pharmaceutical company that can discover, develop and deliver new treatment options in epilepsy and CNS,”
More from news
Approximately 5 fully matching, plus 180 partially matching documents found.
Latest Intelligence
-
Gut instincts lead Takeda to GI pipeline success
that focused the company’s R&D strategy on cutting-edge, innovative approaches in GI, oncology and the central nervous system (CNS).
-
The search for treatments for Parkinson’s disease
CNS disease drug development is traditionally viewed as higher risk and more expensive,” added Dr Roach.” I do not have privileged internal information about Pfizer’s neurological programmes, but many big ... Pfizer is probably in that category, so
-
Rethinking trials: the pros and cons of protocol amendments
We typically see more amendments in oncology and CNS. We also see a higher incidence and average number of amendments in later stage phase 2 and 3 studies.
-
China’s clinical trial shake-up
These reporting rules require sponsors to upload information such as endpoints and eligibility criteria to www.chinadrugtrials.org.cn.
-
Key considerations for disease- modifying Parkinson’s disease trials
By Dr Peter Schueler, Senior Vice President, Drug Development Services and Haichen Yang, Vice President, Global Therapeutic Lead, both at CNS, ICON plc.
More from intelligence
Approximately 0 fully matching, plus 44 partially matching documents found.
Latest appointments
-
Ex-J&J exec Denice Torres joins bluebird bio’s board
During her time at J&J, Torres held several executive leadership roles including president of McNeil Consumer Healthcare and president of Janssen Pharmaceuticals, CNS.
-
New hires at FibroGen, Saniona and Turbine
He is a veteran biotech leader, with over 23 years of experience in rare diseases and CNS.
-
Axovant poaches Allergan’s and Teva’s chief medical and science officers
development. “We have a wonderful opportunity to develop life-changing medicines for patients with CNS diseases.
-
Damien McDevitt moves from GSK to Acadia Pharmaceuticals
At Acadia, which focuses on the development and commercialisation of medicines for central nervous system (CNS) disorders, McDevitt will report to the company’s president and chief executive officer Steve Davis. ... This expertise, combined with his
-
Ron Menezes joins Almirall’s Aqua Pharmaceuticals
Menezes joins the group from Depomed Pharmaceuticals, where he served as vice president of sales and sales operations, pain and CNS.
More from appointments
Approximately 0 fully matching, plus 27 partially matching documents found.
Latest from PMHub
-
Are patient recruitment and retention rates rising or falling?
in central nervous system (CNS) and oncology trials. ... CNS trial dropout rates grew to 25.9% from 19.2. Oncology trial rates grew to 19.3% from 18.2%.
-
New recommendations to stimulate braver and bolder communications
Lilianna Husseini, Director Communications, Oncology, Pfizer Global. Heidi LaPensée, Brand Lead, CNS, Sanofi UK.
-
Diagnosing the lag in neuropsychiatric treatments
Unlike the other organs in our body, the central nervous system (CNS) is surrounded by the Blood Brain Barrier (BBB). ... To say the BBB presents a formidable challenge in CNS drug development is an understatement.
-
Innovative approaches in the treatment of multiple sclerosis
Multiple Sclerosis (MS) is a chronic autoimmune disease that affects the central nervous system (CNS), leading to progressive and permanent disability. ... In the central nervous system (CNS, which includes the brain, optic nerves and spinal cord),
-
Innovative approaches in the treatment of multiple sclerosis
Multiple Sclerosis (MS) is a chronic autoimmune disease that affects the central nervous system (CNS), leading to progressive and permanent disability. ... In the central nervous system (CNS, which includes the brain, optic nerves and spinal cord),
More from PMHub
Approximately 0 fully matching, plus 11 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- New study identifies drugs that are safe to use in COVID-19 treatment
- Novacyt launches diagnostic test to differentiate between COVID-19 and flu
- How COVID-19 is accelerating the threat of antimicrobial resistance
- Relief Therapeutics seeks US emergency approval for COVID-19 drug
- Pfizer’s ALK inhibitor Lorbrena hits the mark in head-to-head lung cancer trial
- Lilly’s Verzenio scores a win in early-stage breast cancer
- Live Webinar: Leveraging Digital Technologies to Create Valuable KOL Engagements & Empower Patients
- Live Webinar: Harnessing Technology to Improve Health and Healthcare
- Novavax starts first phase 3 COVID-19 vaccine trial in the UK
- Lilly’s Verzenio scores a win in early-stage breast cancer
- FDA sets January decision date for Xalkori in ALK-positive lymphoma
- Q&A: Isabel Gibson
Latest intelligence
- Surviving cancer: a new era for patients
- Now more than ever, a shift in perspective is needed...
- Crisis? No problem!
- Issues planning & management for pharma spokespeople, by Andrew Smith...
- Are patient recruitment and retention rates rising or falling?
- First up, the good news. Over the past seven years, clinical trial recruitment rates have been on the rise....
Quick links
Infographics
